JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes-Reference-Cited by-同舟云学术

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

Published:2014-03-06 Issue:10 Volume:123 Page:1544-1551
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Rumi Elisa¹²,Pietra Daniela¹,Ferretti Virginia¹,Klampfl Thorsten³,Harutyunyan Ashot S.³,Milosevic Jelena D.³,Them Nicole C. C.³,Berg Tiina³,Elena Chiara¹,Casetti Ilaria C.²,Milanesi Chiara¹,Sant’Antonio Emanuela²,Bellini Marta²,Fugazza Elena¹,Renna Maria C.²,Boveri Emanuela⁴,Astori Cesare¹,Pascutto Cristiana¹,Kralovics Robert³⁵,Cazzola Mario¹²

Affiliation:

1. Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;

2. Department of Molecular Medicine, University of Pavia, Pavia, Italy;

3. Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;

4. Anatomic Pathology Section, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy; and

5. Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria

Abstract

Key Points JAK2 (V617F)-mutated essential thrombocythemia and polycythemia vera are different phenotypes in the evolution of a single neoplasm. CALR-mutated essential thrombocythemia is a distinct disease entity not only at the molecular level, but also with respect to clinical outcomes.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/10/1544/1374112/1544.pdf

Reference38 articles.

1. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.;Swerdlow,2008

2. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.;James;Nature,2005

3. A gain-of-function mutation of JAK2 in myeloproliferative disorders.;Kralovics;N Engl J Med,2005

4. Genetic and epigenetic complexity in myeloproliferative neoplasms.;Cross,2011

5. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.;Passamonti;Blood,2011

Cited by 474 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular risk in a contemporary cohort of patients with myeloproliferative neoplasms’;Current Research in Translational Medicine;2024-03

2. Cancer-associated thrombosis in hematologic malignancies;International Journal of Hematology;2024-01-25

3. Newly identified roles for PIEZO1 mechanosensor in controlling normal megakaryocyte development and in primary myelofibrosis;American Journal of Hematology;2024-01-02

4. Molecular testing in myeloproliferative neoplasms;Diagnostic Molecular Pathology;2024

5. Cytoreduction for ET and PV: who, what, when, and how?;Hematology;2023-12-08